Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 89 years old
- People diagnosed with liver cancer (called hepatocellular carcinoma, or HCC) that developed alongside a chronic liver condition or scarring of the liver (cirrhosis), regardless of the underlying cause, diagnosed according to specific French medical guidelines updated in June 2021
- People for whom a specialist team meeting has agreed that a combination treatment called Atezolizumab and Bevacizumab is the appropriate systemic (whole-body) treatment, in line with current cancer society recommendations
- People who understand the French language
- People who have been informed about the study and have agreed to take part
Who may not be able to join:
- People living with HIV, a known immune system deficiency, or those taking medications that suppress the immune system
- People with autoimmune diseases (conditions where the immune system attacks the body) or those receiving other types of immunotherapy treatments
- People who have previously had a liver transplant or a procedure to redirect blood flow around the liver (called a portosystemic shunt)
- People who have a serious blood infection (sepsis) or who are taking medications to raise dangerously low blood pressure (vasoconstrictors)
- People who are pregnant or breastfeeding
- People who are legally under guardianship or have a legal curator managing their affairs
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Manon ALLAIRE, Dr, Assistance Publique - Hôpitaux de Paris
Phone: 0142161034
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
evaluate concentration of circulating GPC-3
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.